October #148 : Med Alert! - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

AIDS in the White House

Coming Out Again

AIDS on the Rise?




Greying the Blues

How Many Candles?

Breaking News

For a Tip-Top Ticker

Paying for Pricey Hep C Drugs

Loving Couples

Med Alert!

Sisters in Need

Flu Fighter

TB Test Tune-up

No Money, Mo’ Problems?

Pace Yourself

Make It Count




Amazing Race

Rent Decrease

For Real?

Stripping Stigma

You Said It...

Equal Access For All

How to...Survive a Disaster




Editor's Letter-October 2008

Your Feedback-October 2008

GMHC Treatment Issues-October 2008



 
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


Scroll down to comment on this story.


email print

October 2008


Med Alert!

by Laura Whitehorn

The FDA recently revised the dosing guidelines for the HIV drug Viramune (nevirapine, a member of the non-nuke class), based on new data. Here’s the news: For infants and children, dosing should be based not on weight but on total body surface area (calculated using height and weight). To minimize the risk of developing a rash or other side effects, people prescribed Viramune should begin by taking a half dose for the first two weeks. Now, people who experience the rash can keep taking the initial half dose even after 14 days—but not for more than 28 (if rash persists at that point, a switch is needed). And anyone with moderate or severe liver problems is now advised to avoid Viramune altogether. Search for “Viramune prescribing information updated” at AIDSmeds.com for details.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         

[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    guycmh328
    Columbus
    Ohio


    Loveladyd
    Washington
    DC


    sefarady
    New York
    California


    humboman
    Baltimore
    Maryland
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.